Side Effects and Solutions of CAR-T Treatment

Authors

  • Zhijie Yao

DOI:

https://doi.org/10.62051/htk7aw35

Keywords:

CAR-T; side effects; treatment; CRS.

Abstract

Cancer poses a significant threat to human health. It is a kind of complex and severe diseases characterized by the expanding of abnormal cells in the whole body due to uncontrolled growth. If left untreated, cancer with metastasis can invade nearby tissues, spread to other parts of the body, and impair the normal functioning of organs and systems. There are some treatment methods for it, such as surgery, chemical therapy and radiation. The field of immunology has made tremendous strides in understanding how the immune system works and how it can be harnessed to fight disease. Immunotherapy has become a rising solution in recent years. CAR-T therapy belongs to immunotherapy using genetically modified T cells with receptors of tumor antigens to specifically eliminate cancer cells, which is a promising approach for cancer patients. However, there are still some issues that remain to be resolved to make it wider using in treatment of cancer patients. For example, CAR-T therapy occurs severe side effects sometimes, even induced patients die, although it has been approved application in clinic since 2017, however, limited studies investigated its adverse reactions. Therefore, in the present, the author provides a comprehensive overview of the side effects of CAR-T therapy from reduction of therapeutic effects of antigen escape, to induction patients die of severe cytokine storms, then discusses corresponding treatment measures, which purpose is to help guide treatment for patients, make clinical staff focus on its side effects and provide some ideas for research and development in the future.

Downloads

Download data is not yet available.

References

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J, 2021, 11 (4): 69.

Jogalekar MP, Rajendran RL, Khan F, et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol, 2022, 13: 925985.

Li Y, Ming Y, Fu R, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol, 2022, 13:950923.

Singh N, Maus MV. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity, 2023, 56 (10): 2296 - 2310.

Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol, 2019, 37 Suppl 1: 48 - 52.

Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant, 2019, 25(4):625-638.

Varadarajan I, Lee DW. Management of T-Cell Engaging Immunotherapy Complications. Cancer J, 2019, 25 (3): 223 - 230.

Xin T, Cheng L, Zhou C, et al. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. Front Oncol, 2022, 12: 809754.

Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol, 2018, 15 (1): 31 - 46.

Seo H, González-Avalos E, Zhang W, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol, 2021, 22 (8): 983 - 995.

Downloads

Published

24-03-2024

How to Cite

Yao, Z. (2024). Side Effects and Solutions of CAR-T Treatment. Transactions on Materials, Biotechnology and Life Sciences, 3, 376-380. https://doi.org/10.62051/htk7aw35